Overview

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Status:
Active, not recruiting

Trial end date:
2022-03-12

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery. Chemotherapy drugs, such as nab-paclitaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving nab-paclitaxel, gemcitabine hydrochloride, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Phase:

Phase 2

Details

Lead Sponsor:

OHSU Knight Cancer Institute

Collaborators:

Celgene Corporation
National Cancer Institute (NCI)
Oregon Health and Science University

Treatments:

Albumin-Bound Paclitaxel
Fluorouracil
Gemcitabine
Paclitaxel